tiprankstipranks
Advertisement
Advertisement

MNPR Stock Latest News

Monopar Therapeutics price target raised to $117 from $104 at BTIG
The FlyMonopar Therapeutics price target raised to $117 from $104 at BTIG
5d ago
MNPR
Monopar Wins FDA Rare Pediatric Disease Designation
PremiumCompany Announcements
Monopar Wins FDA Rare Pediatric Disease Designation
6d ago
8K
MNPR
Monopar Therapeutics receives Rare Pediatric Disease designation for ALXN1840
PremiumThe Fly
Monopar Therapeutics receives Rare Pediatric Disease designation for ALXN1840
6d ago
MNPR
Monopar Therapeutics price target raised to $117 from $104 at BTIG
PremiumThe Fly
Monopar Therapeutics price target raised to $117 from $104 at BTIG
6d ago
MNPR
Monopar Highlights Positive Phase 3 Wilson Disease Data
PremiumCompany Announcements
Monopar Highlights Positive Phase 3 Wilson Disease Data
10d ago
8K
MNPR
Monopar Therapeutics announces new FoCus trial analyses
PremiumThe FlyMonopar Therapeutics announces new FoCus trial analyses
10d ago
MNPR
Monopar Shareholders Approve Directors, Pay and Incentive Plan
Premium
Company Announcements
Monopar Shareholders Approve Directors, Pay and Incentive Plan
13d ago
8K
MNPR
Monopar Therapeutics management to meet virtually with Piper Sandler
Premium
The Fly
Monopar Therapeutics management to meet virtually with Piper Sandler
14d ago
MNPR
Monopar: Buy Rating Reiterated as ALXN1840 Data Underpin Valuation and $104 Price Target Maintained
PremiumRatings
Monopar: Buy Rating Reiterated as ALXN1840 Data Underpin Valuation and $104 Price Target Maintained
1M ago
MNPR
Monopar Therapeutics presents ALXN1840-WD-205 data at EASL
PremiumThe Fly
Monopar Therapeutics presents ALXN1840-WD-205 data at EASL
1M ago
MNPR
Monopar Highlights Phase 2 ALXN1840 Data in Wilson Disease
PremiumCompany Announcements
Monopar Highlights Phase 2 ALXN1840 Data in Wilson Disease
1M ago
8K
MNPR
Monopar Showcases ALXN1840 Phase 2 Wilson Disease Data
PremiumCompany Announcements
Monopar Showcases ALXN1840 Phase 2 Wilson Disease Data
2M ago
8K
MNPR
Monopar Buy Rating Reiterated on Advancing ALXN1840 Profile and De-Risked Regulatory Path; $104 Price Target Unchanged
PremiumRatingsMonopar Buy Rating Reiterated on Advancing ALXN1840 Profile and De-Risked Regulatory Path; $104 Price Target Unchanged
2M ago
MNPR
Monopar Highlights Strong Phase 3 Data for ALXN1840
Premium
Company Announcements
Monopar Highlights Strong Phase 3 Data for ALXN1840
3M ago
8K
MNPR
ALXN1840 Poised to Redefine Wilson Disease Treatment Standards: Phase 3 Success, De-Risked Profile, and Buy Rating Justification
Premium
Ratings
ALXN1840 Poised to Redefine Wilson Disease Treatment Standards: Phase 3 Success, De-Risked Profile, and Buy Rating Justification
3M ago
MNPR
Monopar announces new analyses from Phase 3 FoCus trial of ALXN1840
PremiumThe Fly
Monopar announces new analyses from Phase 3 FoCus trial of ALXN1840
3M ago
MNPR
Buy Rating Reaffirmed on ALXN1840 De‑Risking, 2027 Approval Potential, and Strong Cash Runway
PremiumRatings
Buy Rating Reaffirmed on ALXN1840 De‑Risking, 2027 Approval Potential, and Strong Cash Runway
3M ago
MNPR
MNPR Upcoming Earnings Report: What to Expect?
PremiumPre-Earnings
MNPR Upcoming Earnings Report: What to Expect?
4M ago
MNPR
Monopar Appoints Chief Commercial and Strategy Officer Rodriguez
PremiumCompany Announcements
Monopar Appoints Chief Commercial and Strategy Officer Rodriguez
4M ago
8K
MNPR
Monopar Therapeutics appoints Susan Rodriguez as CCSO
PremiumThe FlyMonopar Therapeutics appoints Susan Rodriguez as CCSO
4M ago
MNPR
MNPR: Favorable Risk/Reward on ALXN1840’s Differentiated Profile and De-Risked Regulatory Pathway in Wilson’s Disease
Premium
Ratings
MNPR: Favorable Risk/Reward on ALXN1840’s Differentiated Profile and De-Risked Regulatory Pathway in Wilson’s Disease
5M ago
MNPR
3 Best Stocks to Buy Today, 1/30/2026, According to Top Analysts
Premium
Market News
3 Best Stocks to Buy Today, 1/30/2026, According to Top Analysts
5M ago
ENGN
MNPR

Trending

Name
Price
Price Change
SPX
S&P 500
―
DJIA
Dow Jones
―
NDX
Nasdaq 100
―
More Trending Stocks >